The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

Attention-deficit/hyperactivity disorder (ADHD) is a common but complex neurodevelopmental condition characterized by symptoms of inattention, hyperactivity, and ...

Long-term methylphenidate use in childhood links to higher adult BMI and slightly shorter height, underscoring the need for ...

The agency is currently reviewing the study findings ...

This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...

With an expiration date still more than a year away, here's what the latest details reveal.

For years, people thought that attention deficit hyperactivity disorder (ADHD) was a problem that only kids had. It was ...

Medication and behavioral treatments are both widely used to treat ADHD. While medication is often the first-line treatment, patients who receive behavioral treatments—typically therapy, parent ...